May 1, 2018 / 8:31 PM / 20 days ago

BRIEF-Morphosys, Galapagos initiate IGUANA phase 2 clinical trial with Mor106 in Atopic Dermatitis patients

May 1 (Reuters) - Morphosys Ag:

* DGAP-NEWS: MORPHOSYS AND GALAPAGOS ANNOUNCE INITIATION OF THE IGUANA PHASE 2 CLINICAL TRIAL WITH MOR106 IN ATOPIC DERMATITIS PATIENTS

* PLACEBO CONTROLLED, DOUBLE-BLIND STUDY WILL EVALUATE EFFICACY, SAFETY AND PHARMACOKINETICS (PK) OF MOR106 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below